Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors [Yahoo! Finance]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Drugmakers tumble on reports FDA's top vaccine regulator set to leave [Yahoo! Finance]
Biotech stocks tumble on reports FDA's top vaccine regulator to leave [Yahoo! Finance]